CN105452546B - 与真核细胞调节剂相关的方法和组合物 - Google Patents

与真核细胞调节剂相关的方法和组合物 Download PDF

Info

Publication number
CN105452546B
CN105452546B CN201380057193.8A CN201380057193A CN105452546B CN 105452546 B CN105452546 B CN 105452546B CN 201380057193 A CN201380057193 A CN 201380057193A CN 105452546 B CN105452546 B CN 105452546B
Authority
CN
China
Prior art keywords
antibody
cell
cells
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380057193.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105452546A (zh
Inventor
张洪凯
伊恩·A·威尔森
理查德·A·勒纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CN105452546A publication Critical patent/CN105452546A/zh
Application granted granted Critical
Publication of CN105452546B publication Critical patent/CN105452546B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/746—Erythropoetin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380057193.8A 2012-08-31 2013-08-16 与真核细胞调节剂相关的方法和组合物 Active CN105452546B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261695527P 2012-08-31 2012-08-31
US61/695,527 2012-08-31
US201361814646P 2013-04-22 2013-04-22
US61/814,646 2013-04-22
PCT/US2013/055362 WO2014035693A2 (en) 2012-08-31 2013-08-16 Methods and compositions related to modulators of eukaryotic cells

Publications (2)

Publication Number Publication Date
CN105452546A CN105452546A (zh) 2016-03-30
CN105452546B true CN105452546B (zh) 2018-05-29

Family

ID=50184579

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380057193.8A Active CN105452546B (zh) 2012-08-31 2013-08-16 与真核细胞调节剂相关的方法和组合物

Country Status (10)

Country Link
US (2) US9738719B2 (enExample)
EP (2) EP2966088B1 (enExample)
JP (1) JP6590694B2 (enExample)
CN (1) CN105452546B (enExample)
AU (2) AU2013309272B2 (enExample)
CA (1) CA2883454C (enExample)
DK (1) DK2890836T3 (enExample)
IL (1) IL237479B (enExample)
PT (1) PT2890836T (enExample)
WO (1) WO2014035693A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210517T1 (hr) 2012-12-05 2021-05-14 Novartis Ag Pripravci i postupci za protutijela usmjerena na epo
US9409139B2 (en) 2013-08-05 2016-08-09 Twist Bioscience Corporation De novo synthesized gene libraries
EA201790946A8 (ru) * 2014-12-01 2018-10-31 Зе Скриппс Рисёрч Инститьют Способы и композиции, связанные с функциональными полипептидами, встроенными в гетерологичные белковые каркасы
CA2975852A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
CA3253836A1 (en) 2015-02-04 2025-12-01 Twist Bioscience Corp Compositions and methods for synthetic gene assembly
WO2016172377A1 (en) 2015-04-21 2016-10-27 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
WO2016205784A1 (en) * 2015-06-19 2016-12-22 The Scripps Research Institute Methods and compositions for producing activated natural killer cells and related uses
JP2018525389A (ja) 2015-08-12 2018-09-06 ノバルティス アーゲー 眼障害を治療する方法
AU2016324296A1 (en) * 2015-09-18 2018-04-12 Twist Bioscience Corporation Oligonucleic acid variant libraries and synthesis thereof
CN108698012A (zh) 2015-09-22 2018-10-23 特韦斯特生物科学公司 用于核酸合成的柔性基底
CN108603307A (zh) 2015-12-01 2018-09-28 特韦斯特生物科学公司 功能化表面及其制备
US10233255B2 (en) 2016-04-25 2019-03-19 Sorrento Therapeutics, Inc. Antibody therapeutics that bind STAT3
WO2017214831A1 (zh) * 2016-06-14 2017-12-21 石庆学 特异促进 nrg1 基因高表达的慢病毒载体及其应用
WO2017214832A1 (zh) * 2016-06-14 2017-12-21 石庆学 特异促进 Foxp3 基因高表达的慢病毒载体及其应用
WO2017214829A1 (zh) * 2016-06-14 2017-12-21 石庆学 特异促进 pd-l1 基因高表达的慢病毒表达载体及其应用
WO2017214830A1 (zh) * 2016-06-14 2017-12-21 石庆学 特异促进 pd-1 基因高表达的慢病毒载体及其应用
WO2017214828A1 (zh) * 2016-06-14 2017-12-21 石庆学 特异促进 Prkcz 基因高表达的慢病毒表达载体及其应用
WO2017214910A1 (zh) * 2016-06-15 2017-12-21 石庆学 特异促进Tβ4基因高表达的慢病毒表达载体及其应用
WO2017214945A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 提升Hepcidin基因表达水平的慢病毒表达载体及其应用
CA3034769A1 (en) 2016-08-22 2018-03-01 Twist Bioscience Corporation De novo synthesized nucleic acid libraries
CN110248724B (zh) 2016-09-21 2022-11-18 特韦斯特生物科学公司 基于核酸的数据存储
CN110366613A (zh) 2016-12-16 2019-10-22 特韦斯特生物科学公司 免疫突触的变体文库及其合成
WO2018141058A1 (en) * 2017-01-31 2018-08-09 The Governors Of The University Of Alberta Display of molecules on silently genetically encoded nanoscale carriers for determining synergistic molecular interactions
WO2018156792A1 (en) 2017-02-22 2018-08-30 Twist Bioscience Corporation Nucleic acid based data storage
AU2018234624B2 (en) * 2017-03-15 2023-11-16 Twist Bioscience Corporation De novo synthesized combinatorial nucleic acid libraries
CN110913865A (zh) 2017-03-15 2020-03-24 特韦斯特生物科学公司 免疫突触的变体文库及其合成
IL271205B2 (en) 2017-06-12 2025-02-01 Twist Bioscience Corp Methods for assembling continuous nucleic acids
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
US11407837B2 (en) 2017-09-11 2022-08-09 Twist Bioscience Corporation GPCR binding proteins and synthesis thereof
JP2020536115A (ja) 2017-10-04 2020-12-10 オプコ ファーマシューティカルズ、エルエルシー 癌の個別化療法に関する物品および方法
KR102637566B1 (ko) 2017-10-20 2024-02-16 트위스트 바이오사이언스 코포레이션 폴리뉴클레오타이드 합성을 위한 가열된 나노웰
AU2018383600B2 (en) 2017-12-11 2025-10-02 Abalone Bio, Inc. Yeast display of proteins in the periplasmic space
CN112041438B (zh) 2018-01-04 2025-05-23 特韦斯特生物科学公司 基于dna的数字信息存储
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
EP3827116A4 (en) 2018-07-23 2022-05-11 The Governors of the University of Alberta Genetically-encoded bicyclic peptide libraries
JP7257508B2 (ja) 2018-10-08 2023-04-13 アンバーストーン・バイオサイエンシーズ・インコーポレイテッド 二重特異性および多重特異性生物学的物質の区画化されたアッセイ
CA3124980A1 (en) 2018-12-26 2020-07-02 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
KR20210143766A (ko) 2019-02-26 2021-11-29 트위스트 바이오사이언스 코포레이션 Glp1 수용체에 대한 변이체 핵산 라이브러리
CN113785057A (zh) 2019-02-26 2021-12-10 特韦斯特生物科学公司 用于抗体优化的变异核酸文库
CN113544509A (zh) * 2019-03-08 2021-10-22 牛津遗传学有限公司 选择抗体的方法
JP2022550497A (ja) 2019-06-21 2022-12-02 ツイスト バイオサイエンス コーポレーション バーコードに基づいた核酸配列アセンブリ
AU2020355027A1 (en) 2019-09-23 2022-04-21 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
CA3155629A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for crth2
EP4200434A4 (en) * 2020-08-21 2024-10-02 Hifibio (Shanghai) Co., Ltd. FUNCTIONAL SCREENING USING DROPLET MICROFLUIDIC
EP4253417A4 (en) * 2020-11-24 2024-10-23 Daegu Gyeongbuk Institute Of Science and Technology NEW ANTI-C-MPL ANTIBODY AND ITS USE
KR102579393B1 (ko) * 2020-11-24 2023-09-18 재단법인대구경북과학기술원 신규한 항-c-mpl 항체 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
US20050282181A1 (en) * 2003-12-22 2005-12-22 Wei Yan Methods for identifying functional antibodies
EP2360267A2 (en) * 1998-01-20 2011-08-24 The Board Of Trustees Of The UniversityOf Illinois Yeast cell surface display of proteins and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE114723T1 (de) 1987-03-02 1994-12-15 Enzon Lab Inc Organismus als träger für ''single chain antibody domain (scad)''.
US6969586B1 (en) * 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
US6103879A (en) * 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor
US5980893A (en) * 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO2000055335A1 (en) * 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
EP1169352A4 (en) * 1999-04-14 2005-05-04 Smithkline Beecham Corp ANTIBODY AGAINST THE ERYTHROPOIETIN RECEPTOR
EP1327680B1 (en) * 2000-10-20 2008-04-02 Chugai Seiyaku Kabushiki Kaisha Modified tpo agonist antibody
US20080038265A1 (en) * 2004-04-09 2008-02-14 Reilly Edward B Antibodies to Erythropoietin Receptor and Uses Thereof
HRP20110859T1 (hr) * 2004-12-21 2011-12-31 Medimmune Limited Protutijela usmjerena na angiopoietin-2 i njihova upotreba
CA2625619A1 (en) * 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries
EP2006380A4 (en) * 2006-03-23 2010-08-11 Kyowa Hakko Kirin Co Ltd AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR
AU2007238704A1 (en) * 2006-04-14 2007-10-25 Amgen Inc. Erythropoietin receptor agonists
JP5105468B2 (ja) 2006-12-05 2012-12-26 独立行政法人産業技術総合研究所 細胞内で機能する抗体の創製および細胞表現型を制御するタンパク質の同定
WO2008100816A2 (en) * 2007-02-09 2008-08-21 Medimmune, Llc Antibody libray display by yeast cell plasma membrane
EP2604280A3 (en) * 2008-03-27 2013-10-16 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2360267A2 (en) * 1998-01-20 2011-08-24 The Board Of Trustees Of The UniversityOf Illinois Yeast cell surface display of proteins and uses thereof
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
US20050282181A1 (en) * 2003-12-22 2005-12-22 Wei Yan Methods for identifying functional antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies;Peter M. Bowers 等;《PNAS》;20111220;全文 *
Interleukin-10 Delivery via Mesenchymal Stem Cells: A Novel Gene Therapy Approach to Prevent Lung Ischemia-Reperfusion Injury;Eddie Manning 等;《HUMAN GENE THERAPY》;20100630;全文 *
The human anti-IL-1beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis;Rieke Alten 等;《Arthritis Research & Therapy》;20080630;全文 *

Also Published As

Publication number Publication date
CA2883454C (en) 2022-10-18
US9738719B2 (en) 2017-08-22
WO2014035693A2 (en) 2014-03-06
US20150316561A1 (en) 2015-11-05
US10494438B2 (en) 2019-12-03
CN105452546A (zh) 2016-03-30
EP2890836A2 (en) 2015-07-08
US20180002425A1 (en) 2018-01-04
AU2017202636A1 (en) 2017-05-11
WO2014035693A3 (en) 2014-04-24
PT2890836T (pt) 2019-09-16
IL237479B (en) 2019-08-29
AU2013309272A1 (en) 2015-03-26
EP2966088A2 (en) 2016-01-13
DK2890836T3 (da) 2019-09-16
CA2883454A1 (en) 2014-03-06
EP2890836A4 (en) 2016-04-20
EP2966088B1 (en) 2019-10-16
EP2890836B1 (en) 2019-07-17
AU2013309272B2 (en) 2017-03-09
IL237479A0 (en) 2015-04-30
JP2015529826A (ja) 2015-10-08
EP2966088A3 (en) 2016-04-06
AU2017202636B2 (en) 2019-05-16
JP6590694B2 (ja) 2019-10-16

Similar Documents

Publication Publication Date Title
CN105452546B (zh) 与真核细胞调节剂相关的方法和组合物
US9181322B2 (en) Genetically modified human natural killer cell lines
KR102860449B1 (ko) Cll1을 표적으로 하는 키메라 항원 수용체 및 그의 응용
CN112334479A (zh) 用于治疗感染性疾病的共受体系统
CN113061640B (zh) 用于稳定快速测定抗tigit单克隆抗体药物的生物学活性的方法
US20190358295A1 (en) Methods and compositions for modulating erythropoiesis
Butler et al. Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30
KR20230137948A (ko) Cd19 및 cd22에 결합하는 이중특이적 키메라 항원 수용체
AU2018304173A1 (en) Antigen binding regions against fibronectin type III domains and methods of using the same
KR102536302B1 (ko) Tim-3 에 특이적으로 결합하는 단일클론항체 및 이의 용도
US12209114B2 (en) Chimeric antigen receptor
CN116410332B (zh) 抗间皮素纳米抗体嵌合抗原受体及其应用
US20240189351A1 (en) Il-13ra2 chimeric antigen receptors and methods of use
JP2025507297A (ja) サロゲートサイトカインポリペプチド
CN111484561A (zh) 一种靶向于cd19分子的嵌合抗原受体
Butler Broadening Car T Cell Domain Discovery Through Directed Evolution
Vander Mause et al. Combinatorial T cell engineering eliminates on-target off-tumor toxicity of CD229 CAR T cells while maintaining anti-tumor activity
CN119709799A (zh) 具有自然杀伤蛋白30跨膜结构域的核酸分子及包含其的嵌合抗原受体
WO2025101471A1 (en) Anti-cd27 antibody cell-based biological potency assay
WO2025240496A1 (en) Natural killer cells expressing a mesothelin-targeted chimeric antigen receptor and interleukin-15 for the treatment of solid tumors
WO2025231228A1 (en) Surrogate interferon agonists
Heim Keeping it Simple: Understanding and Engineering Biology with Simple Transmembrane Proteins
London Phage Display for the Development of Synthetic Antibodies Targeting Receptor Tyrosine Kinases
Vander Mause et al. Fast off-rate CD229 chimeric antigen receptor T cells efficiently target multiple myeloma, spare T cells, and exhibit reduced trogocytosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant